Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 10:13:1066369.
doi: 10.3389/fpsyt.2022.1066369. eCollection 2022.

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Jonina Rabinowitz  1 , Shaul Lev-Ran  2   3   4 , Raz Gross  1   3   5
Affiliations

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Jonina Rabinowitz et al. Front Psychiatry. .

Abstract

Objective: Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts ranging from ceremonial use to clinical trials. The aim of this study was to test the hypothesis that past naturalistic use of classic psychedelics would be associated with decreased prevalence of substance use disorder, when controlling for known confounders.

Methods: This cross-sectional study used 2017 NSDUH survey data to evaluate the association between past use of the classic psychedelics LSD, psilocybin and peyote/mescaline and past year substance dependence or abuse. We calculated adjusted odds ratios by multivariate logistic regression, controlling for a range of sociodemographic variables, use of non-psychedelic illicit drugs and mental health related variables.

Results: A total of 56,276 participants were included in this study. Past use of LSD and psilocybin were associated with increased odds of substance dependence or abuse compared to those who had never used psychedelics before, and this was more likely for those who had used LSD more recently. However, prior use of peyote or mescaline was associated with lower odds of past year substance dependence or abuse compared to people who had never used psychedelics before (aOR = 0.68, p < 0.001). Past use of classic psychedelics was not associated with nicotine dependence.

Conclusion: Past use of peyote/mescaline was associated with decreased odds of substance use disorder compared to people who had never used psychedelics before, while past use of LSD or psilocybin was not. It remains unclear whether this difference is due to pharmacological differences between these compounds or simply due to the context in which peyote/mescaline are traditionally taken. Future research should investigate why naturalistic use of different psychedelics is associated with different substance use disorder effects.

Keywords: addiction; mescaline; population study; psychedelic agents; substance use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with the author, SL-R.

References

    1. Tenegra J, Leebold B. Substance abuse screening and treatment. Prim Care. (2016) 43:217–27. 10.1016/j.pop.2016.01.008 - DOI - PubMed
    1. Degenhardt L, Whiteford H, Ferrari A, Baxter A, Charlson F, Hall W, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010. Lancet. (2013) 382:1564–74. 10.1016/S0140-6736(13)61530-5 - DOI - PubMed
    1. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. (2018) 113:1905–26. 10.1111/add.14234 - DOI - PubMed
    1. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. (2018) 5:987–1012. 10.1016/S2215-0366(18)30337-7 - DOI - PMC - PubMed
    1. Volkow N, Boyle M. Neuroscience of addiction: relevance to prevention and treatment. Am J Psychiatry. (2018) 175:729–40. 10.1176/appi.ajp.2018.17101174 - DOI - PubMed